Lista articoli studiati

Somatostatina (SST)

1) SST001 Pollak M.N. and Schally A.V. (1998) Mechanisms of Antineoplastic Action of somatostatin Analogs. Proc Soc Exp Biol Med. 217(2):143-152. (link)

2) SST002 S. Pyronnet et al. (2008) Antitumor effects of somatostatin. Molecular and Cellular Endocrinology 286 (2008) 230–237. (link)

3) SST003 Pai et al (2015) Therapeutic uses of somatostatin and its analogues: Current view and potential applications. Pharmacology & Therapeutics 152: 98-110. (link)

4) SST004 Cascinu et al. (2014) Inhibition of Vascular Endothelial Growth Factor by Octreotide in Colorectal Cancer Patients. Cancer Investigation 19(1), 8–12. (link)

5) SST005 Danesi et al. (1997) Inhibition of Experimental Angiogenesis by the Somatostatin Analogue Octreotide Acetate (SMS 2O1-995). Clinical Cancer Research 3(2):265-72. (link)

6) SST006 Reubi and Laissue (1995) Multiple actions of somatostatin in neoplastic disease. Trends in Pharmacological Sciences 16 (3): 110-115. (link)

7) SST007 Schally A.V. (1998) Oncological Applications of Somatostatin Analogues. Cancer Research 48, 6977-6985. (link)

8) SST008 Schally A.V. et al. (1990) Antitumor effects of analogs of LHRH and somatostatin: experimental anche clinical studies. Journal of Steroid Biochemistry and Molecular Biology 37 (6): 1061-1067 (link)

Recettori della somatostatina (SSTr)

1) SSTr001 Zou Y., et al. (2019) Expression and selective activation of somatostatin receptor subtypes induces cell cycle arrest in cancer cells. Oncology Letters 17: 1723-1731 (link)

Ormone della crescita (GH)

1) GH001 Harvey (2010) Extrapituitary growth hormone. Endocrine 38:335–359. (link)

2) GH002 Subramani et al (2017) Role of Growth Hormone in Breast Cancer. Endocrinology 158(6):1543–1555. (link)

3) GH003 Subramani et al (2014) Growth hormone receptor inhibition decreases the growth and metastasis of pancreatic ductal adenocarcinoma. E xperimental & Molecular Medicine 46. (link)

4) GH004 Kaulsay et al (1999) Autocrine Stimulation of Human Mammary Carcinoma Cell Proliferation by Human Growth Hormone Experimental Cell Research 250, 35–50. (link)

5) GH005 Sustarsic at al. (2013) Human metastatic melanoma cell lines express high levels of growth hormone receptor and respond to GH treatment. Biochemical and Biophysical Research Communications 441(1):144-50. (link)

6) GH006 Kong et al (2016) Human growth hormone and human prolactin function as autocrine/paracrine promoters of progression of hepatocellular carcinoma. Oncotarget 7(20): 29465-79. (link)

7) GH007 Di Bella et al. (2018) The over-expression of GH/GHR in tumour tissues with respect to healthy ones confirms its oncogenic role and the consequent oncosuppressor role of its physiological inhibitor, somatostatin: a review of the literature. Neuroendocrinology Letters 39(4): 101-109. (link)

8) GH008 Basu R. and Kopchick J.J (2019) The effects of growth hormone on therapy resistance in cancer. Cancer Drug Resistance 2:827-846. (link)

9) GH009 Zhu et al. 2020 Growth hormone receptor promotes breast cancerprogression via the BRAF/MEK/ERK signaling pathway. FEBS Open Bio 10(6):1013-1020 (link)

Melatonina (MLT)

1) MLT001 Petronek et al. (2021) Utilization of redox modulating small molecules that selectively act as pro-oxidants in cancer cells to open a therapeutic window for improving cancer therapy. Redox Biology 42:101864. (link)

2) MLT002 Di Bella et al. (2013) Melatonin Anticancer Effects: Review. International Journal of Molecular Science 14, 2410-2430. (link)

3) MLT003 Kvietkauskas et al. (2020) The role of melatonin in colorectal cancer treatment: a comprehensive review. Therapeutic Advances in Medical Oncology 12: 1 –14. (link)

4) MLT004 Wang et al. (2019) Melatonin inhibits lung metastasis of gastric cancer in vivo. Biomedicine & Pharmacotherapy 117, 109018. (link)

5) MLT005 Chen et al. (2020) Melatonin suppresses epithelial to mesenchymal transition in the MG-63 cell line. Molecular Medicine Reports 21: 1356-1364. (link)

6) MLT006 Cheng et al. (2019) Melatonin restricts the viability and angiogenesis of vascular endothelial cells by suppressing HIF-1α/ROS/VEGF. International Journal of Molecular Medicine 43: 945-955. (link)

7) MLT007 Zharinov et al. (2020) Melatonin increases overall survival of prostate cancer patients with poor prognosis after combined hormone radiation treatment. Oncotarget, 11( 41): 3723-3729. (link)

8) MLT008 Maroufi et al. (2020) The potential therapeutic effects of melatonin on breast cancer: An invasion and metastasis inhibitor. Pathology – Research and Practice 216 (2020) 153226. (link)

9) MLT009 Liu et al. (2018) “Melatonin Inhibits Reactive Oxygen Species-Driven Proliferation, Epithelial-Mesenchymal Transition, and Vasculogenic mimicry in Oral Cancer”. Oxidative Medicine and Cellular Longevity, 3510970. (link)

10) MLT010 Fathizadeh et al. (2019) “Melatonin: an anti-tumor agent for osteosarcoma”. Cancer Cell International 19, 319 (link)

Prolattina (PRL)

1) PRL001 Costello (2019) “The Suppression of Prolactin is required for the Treatment of Advanced Prostate Cancer”. Oncogen 2:(3). (link)

2) PRL002 Levina et al. (2009) “Biological Significance of Prolactin in Gynecological Cancers” Cancer Research 69(12): 5226–5233. (link)

3) PRL003 Chou et al. (2021) “Regulation of extracellular and intracellular prolactin on cell proliferation and survival rate through GHR/JAK2/STAT3 pathway in NSCLC” Chemosphere 269:129625. (link)

4) PRL004 Sa-nguanraksa et al. (2020) “The role of Prolactin/Prolactin Receptor polymorphisms and expression in breast cancer susceptibility and outcome” Translational Cancer Research 9(10):6344-6353. (link)

5) PRL005 Sa-nguanraksa et al. (2021) “Expression of long-form prolactin receptor is associated with lower disease-free and overall survival in node-negative breast cancer patients». Gland Surgery 10(1):130-142. (link)

6) PRL006 Ding et al. (2017) “Autocrine Prolactin Stimulates Endometrial Carcinoma Growth and Metastasis and Reduces Sensitivity to Chemotherapy”. Endocrinology 158(6): 1595–1611. (link)

7) PRL007 da Silva et al. (2015) “Prolactin Promotes Breast Cancer Cell Migration through Actin Cytoskeleton Remodeling”. Frontiers in Endocrinology 6:186. (link)

8) PRL008 Kavarthapu et al. (2021) “Crosstalk between PRLR and EGFR/HER2 Signaling Pathways in Breast Cancer.” Cancers 2021: 13, 4685. (link)

9) PRL009 Fei et al. (2017) “Sex-related hormone receptor in laryngeal squamous cell carcinoma: correlation with androgen estrogen-ɑ and prolactin receptor expression and influence of prognosis”. Acta Oto-Laryngologica 138(1): 66-72. (link)

10) PRL010 Harbaum et al. (2010) “Clinicopathological significance of prolactin receptor expression in colorectal carcinoma and corresponding metastases”. Modern Pathology 23; 961-971. (link)

11) PRL011 Hathaway et al. (2021) “Prolactin and Risk of Epithelial Ovarian Cancer”. Cancer epidemiology, biomarkers & prevention 30(9):1652-1659. (link)

12) PRL012 Sethi et al. (2012) “Prolactin and cancer: Has the orphan finally found a home?” pubblicato sul Indian Journal of Endocrinology and Metabolism. 16(Suppl 2): S195–S198. (link)

13) PRL013 Caponnetto et al. (2017) “Prolactin as a Potential Early Predictive Factor in Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab” Oncology 93(1):62-66. (link)

Mutagenesi (MUT)

1) MUT001 Lucien I. (1996) “Tumour Progression: Random Mutations or an Integrated Survival Response to Cellular Stress Conserved from Unicellular Organisms?” Journal of Theoretical Biology 178(4):375-380. (link)

2) MUT002 Michel B. (2005) “After 30 Years of Study, the Bacterial SOS Response Still Surprises Us”. PlosBiology 3(7):1174-1176. (link)

3) MUT003 Ben-Jacop et al. (2012) “Bacterial survival strategies suggest rethinking cancer cooperativity”. Trend in Microbiology 20(9):403-410. (link)

4) MUT004 Cipponi e Thomas (2014) “Stress-induced cellular adaptive strategies: Ancient evolutionarily conserved programs as new anticancer therapeutic targets”. Bioessays 36 (6): 552-560. (link)

5) MUT005 Li et al. (2021) “Non-Coding RNAs in Glioma Microenvironment and Angiogenesis”. Frontiers in Molecular Neuroscience 14. (link)

6) MUT006 Moore et al. (2021) “Exosomes in the Healthy and Malignant Bone Marrow Microenvironment”. In: Banerjee D., Tiwari R.K. (eds) Tumor Microenvironment: Cellular, Metabolic and Immunologic Interactions. Advances in Experimental Medicine and Biology, vol. 1350:67-89. Springer, Cham. (link)

7) MUT007 Matejka e Reindl (2019) “Perspectives of cellular communication through tunneling nanotubes in cancer cells and the connection to radiation effects”. Radiation Oncology 14, 218 (link)

8) MUT008 Kato et al. (2022) “La formazione di tunnel di nanotubi promuove la sopravvivenza contro il 5-fluorouracile nelle cellule di cancro al seno MCF-7 – Tunneling nanotube formation promotes survival against 5‐fluorouracil in MCF‐7 breast cancer cells”. Federation of European Biochemical Societies (FEBS) 12(1): 203–210 (link)

9) MUT009 Pasquier et al. (2013) “Il trasferimento preferenziale dei mitocondri dalle cellule endoteliali alle cellule tumorali attraverso nanotubi a tunnel modula la chemioresistenza – Preferential transfer of mitochondria from endothelial to cancer cells through tunneling nanotubes modulates chemoresistance”. Journal of Translational Medicine, 11:94. (link)

10) MUT010 Desir et al. (2018) “I tunnel di nanotubi indotti dalla chemioterapia mediano l’efflusso di farmaci intercellulari nel cancro del pancreas – Chemotherapy-Induced Tunneling Nanotubes Mediate Intercellular Drug Efflux in Pancreatic Cancer”. Scientific reports 21;8(1):9484 (link)

11) MUT011 Roehlecke e Schmidt (2020) “Tunnelling di nanotubi e microtubi tumorali nel cancro – Tunneling Nanotubes and Tumor Microtubes in Cancer”. Cancers, 12(4), 857 (link)

12) MUT012 Russo et al. (2019) “Mutabilità adattativa dei tumori del colon-retto in risposta a terapie mirate – Adaptive mutability of colorectal cancers in response to targeted therapies.” Science 366 (6472): 1473-1480. (link)

13) MUT013 Lambert et al. (2011) “Un’analogia tra l’evoluzione della resistenza ai farmaci nelle comunità batteriche e nei tessuti maligni – An analogy between the evolution of drug resistance in bacterial communities and malignant tissues”. Nature Reviews Cancer 11, 375–382. (link)

Pubblicazione di dati clinici del Metodo Di Bella (MDB)

1) MDB001 Di Bella et al. (2018) “Il sinergismo di somatostatina, melatonina, retinoidi, vitamin E, D3, C, inibitori prolattinici ed estrogenici, microdosi metronomiche di ciclofosfamide, ha incrementato sopravvivenza, risposte obiettive, performance status, in 297 casi di carcinomi del seno – The Synergism of Somatostatin, Melatonin, Vitamins Prolactin and Estrogen Inhibitors Increased Survival, Objective Response and Performance Status In 297 Cases of Breast Cancer”. Translational Biomedicine 9 No.1:146. (link)

2) MDB002 Di Bella et al. (2012) “Il Metodo Di Bella (MDB) ha migliorato sopravvivenza, la risposta obiettiva e il performance status in uno studio clinico osservazionale retrospettivo su 55 casi di linfomi – The Di Bella Method (MDB) improved survival, objective response and performance status in a retrospective observational clinical study on 55 cases of lymphomas”. Neuro Endocrinology Letters, 33(8):773-781 (link)

3) MDB003 Di Bella et al. (2013) “Il Metodo Di Bella (MDB) nel trattamento del cancro alla prostata: uno studio preliminare retrospettivo su 16 pazienti e una revisione della letteratura – The Di Bella Method (DBM) in the treatment of prostate cancer: a preliminary retrospective study of 16 patients and a review of the literature.” Neuroendocrinology Letters 34(6):523-528 (link)

4) MDB004 Di Bella et al. (2022) Di Bella et al. (2022) ” Uno studio osservazionale retrospettivo su casi di sarcoma trattati con il Metodo Di Bella: razionalità ed efficacia – A retrospective observational study on cases of sarcoma treated with the Di Bella Method: rationale and effectiveness.” World Journal of Pharmaceutical Research 11(7):1219-1278 (link)

Commenti disattivati